CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer
{{output}}
Background: Despite its viral etiology and immunogenic features, cervical cancer shows limited and often short-lived benefit from programmed cell death protein 1 blockade, currently the only approved immunotherapy for this diseas... ...
